allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston, a07305)

Allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) are an investigational cell therapy product being evaluated for the treatment of ischemic stroke. Developed and studied by Sean Savitz and colleagues at the University of Texas Health Science Center at Houston (UTHealth), these cells are administered intravenously during the subacute phase of stroke (typically 3-10 days post-onset). The therapeutic rationale is based on the cells' ability to migrate to sites of injury and modulate the systemic and local immune response. Rather than direct neural replacement, the primary mechanism involves paracrine signaling and immunomodulation, which reduces neuroinflammation, protects the blood-brain barrier, and stimulates endogenous neurorepair and angiogenesis. As an allogeneic product, these cells can be manufactured and stored for "off-the-shelf" use, bypassing the delays associated with autologous cell processing.

Other names

allogeneic BM-MSCsallogeneic mesenchymal stromal cellsMSC Infusion